Adlai NortyeANL +5.90% PS Ratio is 64.42 as of Jul. 06, 2026, which is 2349% above its 10-year median of 2.63. The stock has 7 warning signs investors should review. Among 929 Biotechnology companies, Adlai Nortye ranks worse than 79.98% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Adlai Nortye's share price is $10.05.
Adlai Nortye's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.16. Hence, Adlai Nortye's PS Ratio for today is 64.42.
The historical rank and industry rank for Adlai Nortye's PS Ratio or its related term are showing as below:
ANL'
s PS Ratio Range Over the Past 10 Years
Min: 0.82 Med: 2.63 Max: 102.63
Current: 64.41
During the past 5 years, Adlai Nortye's highest PS Ratio was 102.63. The lowest was 0.82. And the median was 2.63.
ANL's PS Ratio is ranked worse than 79.98% of 929
companies
in the Biotechnology industry
Industry Median: 9.91
vs ANL: 64.41
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Adlai Nortye PS Ratio Related Terms
Adlai Nortye PS Ratio Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Adlai Nortye's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's PS Ratio distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Adlai Nortye's PS Ratio for today is calculated as
Adlai Nortye's Share Price of today is $10.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Adlai Nortye's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Adlai Nortye (ANL) has a PS Ratio of 64.42 as of Jul. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Adlai Nortye and its competitors. This is 2349% above median its historical median of 2.63. Over the past decade, Adlai Nortye's PS Ratio has ranged from 0.82 to 102.63. According to the industry distribution chart, Adlai Nortye ranks #743 out of 929 companies in the Biotechnology industry, placing it in the top 80%.
Is Adlai Nortye's PS Ratio too high?
Adlai Nortye's current PS Ratio of 64.42 is 2349% above median its 10-year median of 2.63. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 102.63. The Biotechnology industry median PS Ratio is 9.91. Adlai Nortye's value of 64.42 is 550.1% above this industry median. Based on the distribution chart, Adlai Nortye ranks #743 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Adlai Nortye's PS Ratio compare to OMER and PRME?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #743 out of 929 companies for PS Ratio. This places Adlai Nortye in the lower half of its industry. The industry median PS Ratio is 9.91. Adlai Nortye's value of 64.42 is 550.1% above this benchmark. Historically, Adlai Nortye's own PS Ratio has ranged from 0.82 to 102.63 over the past decade. While the company's 10-year median is 2.63 vs. the industry median of 9.91, Adlai Nortye has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.91, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adlai Nortye's current PS Ratio of 64.42 is 550.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median PS Ratio is 9.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current PS Ratio is 64.42, which is 2349% above median its own 10-year median of 2.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current PS Ratio of 64.42. The current PS Ratio is 64.42, which is 2349% above median its 10-year median of 2.63 and 550.1% above the Biotechnology industry median of 9.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Adlai Nortye (ANL), the current PS Ratio is 64.42 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 